Delivery Order VA25913D0313-VA25913J4015

The National Institutes of Health National Institute on Drug Abuse awarded a $288,375 firm fixed price purchase order to Curia Global Inc., doing business as Amri, to provide non-GMP synthesis of up to 100 ligands that bind the KIAA0203 protein. Under the terms of the contract, Amri will synthesize the ligands in 2-10 milligram quantities over a one-year period of performance. Amri must dedicate two full-time scientists and one part-time scientist at 25% effort to update progress. There is no...

The Department of Health and Human Services Food and Drug Administration awarded a definitive contract valued at $831,964 to Research Center Pharmaceutical Engineering GmbH. The firm fixed price contract is to provide services in support of the project titled "OCT for Real-Time Monitoring of Coating Process Dynamics & Product Quality" and will involve work by the prime contractor and its parent organization, Technische Universitaet Graz. The contract has a period of performance...

This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to Altasciences Clinical Kansas Inc., a for-profit contract research organization (CRO). The $1,340,461.88 firm fixed-price delivery order is for a clinical trial to assess the safety, tolerability, and pharmacokinetics of an investigational agent for substance use disorder (SUD) treatment. The contract is part of NIDA's $21 million indefinite delivery contract N01DA-23-8935, which supports...

The National Institute on Drug Abuse awarded a $7.02 million definitive contract to Research Triangle Institute for analytical chemistry and stability testing of substance use disorder treatment drugs on August 4, 2024, under cost-plus-fixed-fee pricing with no set-aside. The three-year base period runs from August 4, 2024 through August 3, 2027, with options extending the ultimate completion date to August 3, 2029. Place of performance is Durham, North Carolina. The originating solicitation...

This is a $3,562,513 cost-plus-fixed-fee definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to Altasciences Clinical Kansas Inc. The contract is for pharmacokinetic and pharmacodynamic studies to support the development of medications for substance use disorders. The contract period of performance is from September 20, 2017 to September 19, 2022, with an ultimate completion date of July 31, 2025. This award is not associated...

This federal contract award to PPD Development LP, a global contract research organization (CRO), provides regulatory consulting assistance for a medical device developer under the Blueprint MedTech program. The $370,621 cost-plus-fixed-fee contract includes research and development for clinical studies, pre-submission assessment, and package preparation. The award is issued by the National Institute on Drug Abuse, a civilian agency, and is not set aside. PPD Development LP is a subsidiary of...

The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a firm fixed-price purchase order valued at $22,500 to the University of Kansas Center for Research, Inc. This award is pursuant to a request for quote to develop a manufacturable tablet formulation of the compound NCGC72 for use in dog sarcoma clinical studies. The prime contractor will non-GMP manufacture 1,500 tablets total, with 1,000 tablets at 50mg dosage and 500 tablets at...

This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...

The National Institute on Drug Abuse awarded a delivery order valued at $827,787.59 to Bachem Americas Inc. for the manufacture of 1 kilogram of current Good Manufacturing Practice (cGMP) L-enkephalin (L-ENK) and related contract research organization (CRO) support services for drug substance development and manufacturing. The award was issued on September 18, 2020, with an ultimate completion date of August 31, 2024. This delivery order falls under Bachem Americas' larger Indefinite...

This federal contract award was made by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization specializing in early phase drug development services. The $1,293,840.24 firm fixed price definitive contract is for a project on the pharmacokinetics study of an opioid drug product following insufflation of milled drug products. The contract has an ultimate completion date of September 30, 2019 and was awarded on September 17, 2015. No...